LI Kang Biomedical (6242) reported revenue of NT$53 million for Oct 2026, -8.1% year on year and +26.4% from the previous month. Revenue for Jan–Oct 2026 was NT$457.5 million (-3.7% year on year).
In Oct 2026, it ranked No. 97 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$53 million | -8.1% | +26.4% |
| Sep 2026 | NT$41.9 million | +7.6% | +13.2% |
| Aug 2026 | NT$37 million | -0.5% | -12.0% |
| Jul 2026 | NT$42.1 million | -0.1% | -15.6% |
| Jun 2026 | NT$49.9 million | -8.3% | -14.1% |
| May 2026 | NT$58 million | +7.9% | +7.2% |
| Apr 2026 | NT$54.1 million | -4.2% | +1.1% |
| Mar 2026 | NT$53.5 million | -7.9% | +119.5% |
| Feb 2026 | NT$24.4 million | -44.6% | -44.2% |
| Jan 2026 | NT$43.7 million | +33.6% | -20.3% |
| Dec 2025 | NT$54.8 million | +3.3% | -7.4% |
| Nov 2025 | NT$59.2 million | +10.2% | +2.6% |
| Oct 2025 | NT$57.6 million | +0.8% | +48.1% |
| Sep 2025 | NT$38.9 million | -20.7% | +4.7% |
| Aug 2025 | NT$37.2 million | -1.7% | -11.6% |
| Jul 2025 | NT$42.1 million | +4.3% | -22.6% |
| Jun 2025 | NT$54.4 million | +18.2% | +1.2% |
| May 2025 | NT$53.7 million | +1.9% | -4.8% |
| Apr 2025 | NT$56.5 million | +8.6% | -2.9% |
| Mar 2025 | NT$58.1 million | +4.1% | +32.2% |
| Feb 2025 | NT$44 million | +57.6% | +34.5% |
| Jan 2025 | NT$32.7 million | -17.9% | -38.3% |
| Dec 2024 | NT$53 million | -4.3% | -1.3% |
| Nov 2024 | NT$53.7 million | -9.5% | -6.1% |
| Oct 2024 | NT$57.2 million | +0.3% | +16.5% |
Jan–Oct 2026 cumulative: NT$457.5 million (-3.7% YoY)
Other Biotech & Medical companies
Compare with peers: LI Kang Biomedical vs PEC / LI Kang Biomedical vs Lotus Pharm / LI Kang Biomedical vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16